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Prolonged norovirus shedding may occur in certain patients, such as organ transplant recipients. We established a mouse
model for persistent norovirus infection (using the mouse norovirus MNV.CR6 strain). The nucleoside viral polymerase
inhibitor 2=-C-methylcytidine (2CMC), but not favipiravir (T-705), reduced viral shedding to undetectable levels. Viral
rebound was observed after stopping treatment, which was again effectively controlled by treatment with 2CMC. No drug-
resistant variants emerged.
Noroviruses are an important cause of chronic gastroenteritisin immunocompromised patients (1). Although most noro-
virus infections are acute and self-limiting, the infection can be-
come chronic in (i) solid-organ and hematopoietic stem cell
transplant recipients (2–4), (ii) patients undergoing chemother-
apy (3, 5, 6), and patients with immunodeficiencies, including
those caused by HIV infection (7–10). Prolonged norovirus infec-
tion can also be observed in young children (11) and the elderly
(12, 13). Reduction of immunosuppressive therapy, when feasi-
ble, is the strategy of choice to control the infection in transplant
recipients. Specific antiviral therapy to treat (chronic) norovirus
gastroenteritis is not available. The effect of drugs such as ribavi-
rin and nitazoxanide has been evaluated in a small number of
patients, but no clear beneficial clinical effect was observed (10,
14, 15).
We wanted to establish a persistent mouse norovirus (MNV)
infection model that can be used to assess the efficacy of norovirus
inhibitors on such an infection. To that end, the MNV.CR6 strain
(herein CR6) was employed. MNV is a genogroup V norovirus
that has been widely used as a surrogate for human noroviruses
(16, 17); CR6 is an avirulent MNV strain that can replicate for
weeks to months in wild-type mice and (to higher titers) in innate
immune-deficient mice (18, 19). The MNV.CR6 strain was shown
to replicate at higher titers in the proximal colon but was also
detected in the mesenteric lymph nodes, spleen, brain, liver, and
lungs of mice 3 days after infection (18, 20). The site of persistence
is reported to be the intestine, where CR6 is present for many
weeks after infection (20). It was recently shown that both wild-
type and IFNAR/-positive mice were cured of an ongoing
MNV.CR6 infection following treatment with gamma interferon
(IFN-) (21).
Interferon receptor knockout mice (AG129) were infected
orally with the CR6 strain (22), and the effects of two small-mol-
ecule inhibitors of in vitro norovirus replication (2=-C-methylcy-
tidine [2CMC] and favipiravir [T-705]) on viral shedding in stool
were assessed (23, 24). We demonstrated earlier that 2CMC is
effective in the treatment and prophylaxis of acute MNV infection
in AG129 mice (25).
2CMC was synthesized as described previously (26) and dis-
solved in sterile saline. Favipiravir (T-705) was purchased from
BOC Sciences (NY, USA) and formulated in 0.4% carboxymeth-
ylcellulose (Sigma-Aldrich, Bornem, Belgium). The MNV.CR6
strain (kindly provided by H. W. Virgin, Washington University,
St. Louis, MO, USA) was propagated in RAW 264.7 as described
before (24).
AG129 mice (129/Sv mice) originally from BK Universal,
United Kingdom, were bred and housed at the Rega Institute
under specific-pathogen-free conditions. All experiments were
performed under the guidelines and authorization of the Eth-
ical Committee of the University of Leuven (P101/2012). For
all experiments, age- and sex-matched mice 8 to 12 weeks of age
were infected by oral gavage with 106 CCID50 (50% cell culture
infective doses) of CR6. At 7 days postinfection (p.i.), mice
were left untreated (n 9) or were treated with 100 mg/kg daily
of 2CMC subcutaneously for 5 (n 4), 7 (n 4), or 11 (n 4)
days. Two more rounds of a 14-day treatment (with an 4-
week interval in between) with 2CMC (n  10) or favipiravir
(200 mg/kg daily by oral gavage [n  5]) were given. On each
day after infection, the general condition and weight of treated
and untreated mice were assessed, individual stool samples
were collected (whenever possible during one daily period of
observation), and levels of MNV RNA were quantified by re-
verse transcriptase quantitative PCR (RT-qPCR). RNA was ex-
tracted from stool samples using the RNeasy minikit (Qiagen,
The Netherlands) according to the manufacturer’s protocol.
For the MNV RT-qPCR, the primers and probe were used as
described before, with minor modifications (24). The iTaq
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Universal Probes reaction mix (Bio-Rad, Belgium) was used,
and cycling conditions included reverse transcription at 50°C
for 10 min and initial denaturation at 95°C for 3 min, followed
by 40 cycles of denaturation at 95°C for 15 s, annealing, and
extension at 60°C for 30 s (Roche LightCycler 96; Roche Diag-
nostics, Belgium). Statistical analysis was performed using
Prism 5 software (Graph-Pad Software, San Diego, CA). P val-
ues were determined with the nonparametric Mann-Whitney
test.
Following oral infection with CR6, all AG129 mice re-
mained healthy and did not show symptoms (e.g., ruffled fur,
reduced activity, squinted eyes, diarrhea, or weight loss) that
are typically observed in mice infected with MNV-1, a strain
that causes acute infections (Fig. 1A). The consistency of the
stool of infected animals remained normal throughout the ex-
periment (data not shown), but viral RNA was detected from
day 2 or 3 p.i. on in some of the animals (Fig. 1B). From day 6
p.i. on, viral RNA was consistently detected at high titers in the
stool of all infected mice (at 4 log10 RNA copies/g of stool in
most mice). A parallel quantification of infectious virus parti-
cles was performed by endpoint titration (CCID50 determina-
tion) in stool samples collected in parallel and rendered com-
parable results and limits of detection (2.58 log10 CCID50/g
stool versus 1.81 log10 RNA copies/g stool) as shown in Fig. S1
in the supplemental material. Hence, the RT-qPCR has an ad-
equate sensitivity to detect (reduced) MNV levels in infected
mice.
Day 7 p.i. was selected as the start of treatment with 2CMC
for 5, 7, or 11 consecutive days (Fig. 2A). Shedding of virus in
the stool was quantified to monitor whether the inhibitor(s)
can (i) reduce or even stop viral shedding and (ii) completely
cure the animal of the infection. Treatment with 2CMC re-
sulted in a significant reduction in virus shedding in the stool as
early as 1 day after the start of treatment (day 8 p.i.) (reduction
of 1.7 log10 RNA copies/g of stool in 2CMC-treated mice versus
untreated mice) (Fig. 2). At day 14 p.i., i.e., after 7 days of
treatment, CR6 RNA had become undetectable in the stool of
all 2CMC-treated mice. Viral RNA remained undetectable in
the stool of the 2CMC-treated animals until the end of treat-
ment at day 17 p.i. (end of the 11-day treatment) (Fig. 2A).
However, 3 days after the 11-day 2CMC-treatment period, vi-
ral RNA was again detectable in the stool of mice at levels
comparable to those of the untreated controls (Fig. 2E). Hence,
2CMC treatment for 11 days proved insufficient in com-
pletely eliminating CR6 from the infected mice. Also, soon
after cessation of the 5- or 7-day treatment period, rebound
was observed in all mice.
Next, the effect of a treatment scheme consisting of two
rounds of 14 consecutive days of 2CMC treatment (with a
pause of 4 weeks in between) was evaluated; in parallel, the
effect of favipiravir (for which we have demonstrated in vitro
anti-MNV activity, [24]) was assessed (Fig. 3). In 6 of 10
2CMC-treated mice, CR6 RNA was undetectable in stool fol-
lowing another 14 days of treatment (day 21 p.i.). Similar to the
experiment presented in Fig. 2, a rebound in viral RNA was
noted following cessation of the treatment. Favipiravir did not
reduce viral shedding (Fig. 3A). The dose selected for the study
was determined on the basis of the solubility and stability of the
formulation; this dose had also been shown to be effective
against infection with yellow fever and West Nile virus in small
models (27, 28). The in vitro activity of favipiravir against these
flaviviruses is comparable to the activity of the compound
against the murine norovirus (23, 29). In a recent study, 8
weeks of treatment with 600 mg/kg daily of favipiravir resulted
in undetectable levels of MNV-3 RNA in the stool of some of
the infected mice (30). At day 55 p.i. (i.e., about 4 weeks after
stopping the first round of treatment), both of the groups
treated earlier were again treated with either compound for 14
consecutive days (Fig. 3B). The second treatment round with
favipiravir did not result in a reduction in viral shedding (Fig.
3B). The second round of 14-day treatment with 2CMC again
proved to be effective in reducing the shedding of virus in the
stool to undetectable levels (Fig. 3B), but following cessation of
treatment, viral rebound was observed. Despite the fact that
viral rebound was observed after the first 14-day 2CMC treat-
ment period, the infection was still susceptible to the drug,
suggesting that no drug-resistant variants had emerged. We
tried but failed to sequence viral RNA isolated from stool sam-
ples at days 69 and 71 p.i. (which followed the end of treat-
ment). We next attempted to sequence samples from day 16
FIG 1 Weight variation SEM (A) and viral RNA loads in stool samples (B)
of MNV.CR6-infected AG129 mice. Data in panel B are presented as log10
RNA copy numbers per gram of stool for each group. Dotted line, limit of
detection.
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(Fig. 2C) and day 22 (Fig. 2E), which had titers that were 1 log10
higher. For that, we used the RT-qPCR reverse primer and the
forward primer 5=-GAGAACACCCTTGAACCACA-3= (posi-
tions 3823 to 3843) to perform an RT-PCR. A 50-l reaction
mixture containing 5 l of sample, 34 l of H2O, 10 l of 5	
Qiagen One Step RT-PCR buffer, 2 l of deoxynucleoside
triphosphates, 0.6 M of each primer, and 2 l of RT-PCR
enzyme mix was used. Cycling conditions included reverse
transcription at 50°C for 30 min and activation of HotStar Taq
at 95°C for 15 min, followed by 40 cycles of initial denaturation
at 94°C for 30 s, annealing at 60°C for 30 s, and extension at
72°C for 1 min and final extension at 72°C for 10 min. The
resulting amplicon (1,200 bp) was gel purified (Wizard SV
gel and PCR clean-up system; Promega), and PCR fragments of
both DNA strands were analyzed using the cycle sequencing
method (BigDye Terminator kit; PerkinElmer Life Sciences).
No mutations were present in the four different samples with
high coverage, two untreated mice at days 16 and 22 p.i. and
two treated mice at day 22 p.i.
Although 2CMC is a relatively weak in vitro inhibitor of MNV
replication, the compound effectively reduces virus shedding in
the feces of mice chronically infected with MNV. Also, no drug
resistance developed. Favipiravir, despite inhibiting in vitro MNV
replication, was not effective in the mouse model. The activity of
2CMC in this chronic mouse infection model suggests that a
(more) potent inhibitor of norovirus replication would be able to
at least reduce viral replication in patients with chronic norovirus
infections. In such patients, it is very important that drug-resistant
variants not develop. Hence, antinorovirus drugs (e.g., 2CMC)
should not readily select for drug-resistant variants; alternatively,
a combination of drugs may also prevent the development of re-
sistance.
In conclusion, we demonstrated for the first time that an in-
hibitor of norovirus replication can reduce viral shedding to un-
detectable levels in chronically infected animals. This validates this
model for the evaluation of the potential in vivo efficacy of novel
norovirus inhibitors.
FIG 2 (A) Scheme of CR6 infection and treatment with 2CMC at 100 mg/kg daily for 5, 7, or 11 days starting on day 7 p.i. (B) Viral RNA loads in stool samples
of MNV.CR6-infected AG129 mice that were untreated (n 9) or treated with 2CMC at 100 mg/kg daily starting on day 7 p.i. for a period of 5 (n 4), 7 (n
4), or 11 (n 4) days. Data are presented only for mice that received treatment; values in brackets are the numbers of treated mice at particular time points. (C,
D, E) Follow-up period after the end of 5, 7, or 11 days of treatment, respectively. Dotted line, limit of detection.P values were determined with the nonparametric
Mann-Whitney test: ***, P
 0.001; **, P
 0.01; ns, P 0.05.
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